Psilocybin for Chronic Pain: What the Research Shows
Chronic pain affects approximately 50 million Americans and is one of the leading causes of disability. Standard pain management (opioids, NSAIDs, nerve blocks) addresses symptoms without treating the underlying sensitization of pain circuits. Psilocybin has shown surprising promise for several chronic pain conditions.
Cluster Headaches: The Most Striking Evidence
Cluster headaches — sometimes called "suicide headaches" for their severity — are one of the most treatment-resistant pain conditions. Anecdotal reports of psilocybin's effectiveness for cluster headaches have been circulating in patient communities since the early 2000s. A 2006 survey of 53 cluster headache patients who self-administered psilocybin found that 22 of 26 who used psilocybin reported cluster period termination or significant reduction in attack frequency.
A formal clinical trial at Yale is currently studying psilocybin for cluster headaches. Preliminary results are promising.
Phantom Limb Pain
Phantom limb pain — pain experienced in an amputated limb — involves maladaptive neuroplasticity: the brain's representation of the missing limb becomes hyperactive. Psilocybin's neuroplasticity-promoting effects appear to help reorganize these representations. A 2022 case series at UCSF found significant phantom limb pain reductions in three of four patients after two psilocybin sessions.
Fibromyalgia
Fibromyalgia involves central sensitization — the brain's pain-processing circuits become hyperreactive. Psilocybin's 5-HT2A activation reduces this sensitization. A 2023 observational study found that fibromyalgia patients who microdosed psilocybin reported 40% reductions in pain intensity scores over 8 weeks.